The RAMP1 gene (Receptor Activity Modifying Protein 1) encodes a single-transmembrane-domain accessory protein that is crucial for the proper function of certain G protein-coupled receptors (GPCRs) ^[1]. Its primary role is to chaperone the calcitonin receptor-like receptor (CRLR) to the cell surface and to determine its ligand specificity. When co-expressed with CRLR, RAMP1 forms the functional receptor for calcitonin gene-related peptide (CGRP), a potent vasodilator. RAMP1 is involved in the terminal glycosylation, maturation, and presentation of the CGRP receptor ^[2]. Gene expression of RAMP1 is observed in a wide range of cellular tissues, including those in the brain (hypothalamus, brainstem, cortex), adrenal gland, alimentary system, bone, reproductive system, various muscle tissues (psoas muscle, skeletal muscle, muscle of trunk), and immune cells like natural killer cells, T-cells, B-cells, and CD14-positive monocytes ^[3]. Dysregulation of RAMP1 is associated with several diseases, most notably migraine, but also conditions like essential hypertension, cerebral infarction, acute lung injury, chronic inflammation, certain cancers (e.g., prostate cancer, gastric cancer), and metabolic disorders ^[3-4].

The B6-hRAMP1 mouse is a humanized model, constructed by replacing the partial coding sequences of mouse Ramp1 exon 1 with the Kozak-human RAMP1 CDS-3'UTR of mouse Ramp1-WPRE-BGH pA cassette. B6-hRAMP1 mice can be used for research into the pathogenesis of migraine, essential hypertension, cerebral infarction, acute lung injury, chronic inflammation, certain cancers, and metabolic disorders. They are also useful for the screening, development, and safety evaluation of RAMP1-targeted drugs.